Sun Pharma Advanced Research Company Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Sun Pharma Advanced Research Company (SPARC) has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for US $195 million upon the closing of the transaction.

PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby? indicated for the treatment of neonatal seizures.

?The sale of the PRV will enable us to accelerate the development of our pipeline assets and strengthen our external innovation strategy, which has already delivered multiple additions to our portfolio,? said Anil Raghavan, CEO of SPARC. The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act.

Stifel acted as the exclusive financial advisor to SPARC with respect to this transaction.

Sun Pharma Advanced Research Company announced that Dr. Shravanti Bhowmik, Head of Operations Management, and a member of Senior Management Team of the Company has resigned from her position in the Company with effect from the close of business hours on 31 March 2026.

Net Loss of Sun Pharma Advanced Research Company reported to Rs 80.42 crore in the quarter ended December 2025 as against net loss of Rs 79.51 crore during the previous quarter ended December 2024. Sales declined 43.33% to Rs 8.45 crore in the quarter ended December 2025 as against Rs 14.91 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 9 February 2026.

Powered by Capital Market - Live News